Strategies for reduction in duration of antibiotic use in hospitalized patients.

There is a global crisis of antibiotic resistance in part because of the collateral damage of antibiotic use. Reduction in antibiotic consumption is clearly important to minimize this problem. Limiting treatment duration may be the most clinically palatable means of reducing antibiotic consumption. Antimicrobial stewardship programs play an important role in this process. Their effectiveness may be increased by drawing on evidence from randomized controlled trials regarding optimal antibiotic duration. However, in most clinical scenarios, the recommended duration of therapy in published guidelines is based on expert opinion. Biological markers, such as procalcitonin, have been shown to reduce antimicrobial consumption with no adverse outcome in 11 randomized controlled trials. Although procalcitonin may not be the perfect biomarker, the concept of procalcitonin-guided antibiotic discontinuation after clinical stabilization, in conjunction with antimicrobial stewardship programs, appears to be ready for introduction into clinical practice.

[1]  F. Tubach,et al.  Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial , 2010, The Lancet.

[2]  E. P. Dellinger,et al.  Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  S. Marsch,et al.  Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study , 2009, European Respiratory Journal.

[4]  T. Bregenzer,et al.  Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. , 2009, JAMA.

[5]  D. Warren,et al.  Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  B. Bein,et al.  Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial , 2009, Critical care.

[7]  M. Sodemann,et al.  Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission--a randomized trial. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[8]  Soumitra R. Eachempati,et al.  Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients? , 2009, The Journal of trauma.

[9]  C. Bauer,et al.  One or three weeks' treatment of acute pyelonephritis? A double-blind comparison, using a fixed combination of pivampicillin plus pivmecillinam. , 2009, Acta medica Scandinavica.

[10]  E. Schleicher,et al.  Inflammation markers in point-of-care testing (POCT) , 2009, Analytical and bioanalytical chemistry.

[11]  B. Bein,et al.  Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study , 2009, Langenbeck's Archives of Surgery.

[12]  M. Briel,et al.  Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. , 2008, Archives of internal medicine.

[13]  M. Falagas,et al.  Short- versus long-course antibiotic therapy for acute pyelonephritis in adolescents and adults: a meta-analysis of randomized controlled trials. , 2008, Clinical therapeutics.

[14]  古谷 良輔,et al.  Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. , 2008, American journal of respiratory and critical care medicine.

[15]  J. Pugin,et al.  Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. , 2008, American journal of respiratory and critical care medicine.

[16]  K. Becker,et al.  Procalcitonin assay in systemic inflammation, infection, and sepsis: Clinical utility and limitations , 2008, Critical care medicine.

[17]  L. Rice The Maxwell Finland Lecture: for the duration-rational antibiotic administration in an era of antimicrobial resistance and clostridium difficile. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  H. Evans,et al.  Duration of antibiotic therapy for ventilator-associated pneumonia caused by non-fermentative gram-negative bacilli. , 2007, Surgical infections.

[19]  E. Rubinstein Short antibiotic treatment courses or how short is short? , 2007, International journal of antimicrobial agents.

[20]  L. Mandell,et al.  Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. , 2007, The Journal of antimicrobial chemotherapy.

[21]  A. Fisher,et al.  A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis , 2007, Current medical research and opinion.

[22]  D. Moore,et al.  Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. , 2007, The American journal of medicine.

[23]  J. Kline,et al.  Procalcitonin test in the diagnosis of bacteremia: a meta-analysis. , 2007, Annals of emergency medicine.

[24]  T. Dellit Summary of the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship , 2007 .

[25]  J. Bartlett,et al.  Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  Anthony S McLean,et al.  Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. , 2007, The Lancet. Infectious diseases.

[27]  M. Christ-Crain,et al.  Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. , 2006, American journal of respiratory and critical care medicine.

[28]  Patrick Nicolas,et al.  Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: A systematic review and meta-analysis , 2006, Critical care medicine.

[29]  C. Weenink,et al.  Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study , 2006, BMJ : British Medical Journal.

[30]  J. Domínguez-Roldán,et al.  Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: a prospective observational study , 2006, Critical care.

[31]  A. Anzueto,et al.  Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. , 2006, Chest.

[32]  L. Pinoges,et al.  Ceftriaxone as effective as long-acting chloramphenicol in short-course treatment of meningococcal meningitis during epidemics: a randomised non-inferiority study , 2005, The Lancet.

[33]  J. Lacroix,et al.  Erratum: Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: A systematic review and meta-analysis (Clinical Infectious Diseases (July 15, 2004) 39 (206-217)) , 2005 .

[34]  A. MarioCalvo,et al.  Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults. A randomized trial. Chastre J, Wolff M, Fagon JY, Chevret S et al. JAMA 2003; 290: 2588-98 , 2004 .

[35]  Allan R Tunkel,et al.  Practice guidelines for the management of bacterial meningitis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  D. Dooley,et al.  Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. , 2004, Archives of internal medicine.

[37]  M. Niederman,et al.  Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. , 2004, The Journal of antimicrobial chemotherapy.

[38]  T. File,et al.  Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. , 2004, Respiratory medicine.

[39]  France Gauvin,et al.  Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  S. Roberts,et al.  Short course intravenous benzylpenicillin treatment of adults with meningococcal disease , 2004, Internal medicine journal.

[41]  G. Bertolini,et al.  Antibiotic usage in intensive care units: a pharmaco-epidemiological multicentre study. , 2004, The Journal of antimicrobial chemotherapy.

[42]  Marin H Kollef,et al.  A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. , 2004, Chest.

[43]  J. Xiang,et al.  Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens , 2004, Current medical research and opinion.

[44]  M. Christ-Crain,et al.  Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial , 2004, The Lancet.

[45]  Michel Wolff,et al.  Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. , 2003, JAMA.

[46]  R. Wunderink,et al.  Erratum: High-dose, short-course levofloxacin for community-acquired pneumonia: A new treatment paradigm (Clinical Infectious Diseases (2003) 37 (752-60)) , 2003 .

[47]  Leon G Smith,et al.  High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  Mark Thomas,et al.  Three days of intravenous benzyl penicillin treatment of meningococcal disease in adults. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[49]  P. Martín-Dávila,et al.  Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[50]  V L Yu,et al.  Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. , 2000, American journal of respiratory and critical care medicine.

[51]  H. Schächinger,et al.  Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit , 2000, Critical care medicine.

[52]  J. Reuning-Scherer,et al.  Comparison of Ciprofloxacin (7 Days) and Trimethoprim-Sulfamethoxazole (14 Days) for Acute Uncomplicated Pyelonephritis in Women , 2000 .

[53]  A. Schaeffer,et al.  Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women , 1999 .

[54]  R. Siegel,et al.  Comparison of 7 versus 10 days of antibiotic therapy for hospitalized patients with uncomplicated community-acquired pneumonia: a prospective, randomized, double-blind study. , 1999, American journal of therapeutics.

[55]  D. Durack,et al.  Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. Endocarditis Treatment Consortium Group. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[56]  I. Ocaña,et al.  Effectiveness of Cloxacillin with and without Gentamicin in Short-Term Therapy for Right-Sided Staphylococcus aureus Endocarditis , 1996, Annals of Internal Medicine.

[57]  P. Francioli,et al.  Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 days: a prospective multicenter study. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[58]  J. Verhoef,et al.  A sequential study of intravenous and oral Fleroxacin for 7 or 14 days in the treatment of complicated urinary tract infections. , 1995, International journal of antimicrobial agents.

[59]  M. Dinubile,et al.  Short-Course Antibiotic Therapy for Right-Sided Endocarditis Caused by Staphylococcus aureus in Injection Drug Users , 1994, Annals of Internal Medicine.

[60]  A. Vergara,et al.  Prospective evaluation of a two-week course of intravenous antibiotics in intravenous drug addicts with infective endocarditis , 1994, European Journal of Clinical Microbiology and Infectious Diseases.

[61]  R. T. Miller,et al.  Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy. , 1988, Annals of internal medicine.

[62]  W. Stamm,et al.  Acute renal infection in women: treatment with trimethoprim-sulfamethoxazole or ampicillin for two or six weeks. A randomized trial. , 1987, Annals of internal medicine.

[63]  R. Gleckman,et al.  Therapy of symptomatic pyelonephritis in women. , 1985, The Journal of urology.

[64]  R. L. Thompson,et al.  Short-term therapy for streptococcal infective endocarditis. Combined intramuscular administration of penicillin and streptomycin. , 1981, JAMA.

[65]  S. Kaplan,et al.  Successful two-week treatment schedule for penicillin-susceptible streptococcus viridans endocarditis. , 1971, Lancet.

[66]  A. Fisher,et al.  A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. , 2008, Urology.

[67]  M. Christ-Crain,et al.  Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. , 2007, Chest.

[68]  P. Léophonte,et al.  Efficacité comparée de la ceftriaxone dans un traitement de dix jours versus un traitement raccourci de cinq jours des pneumonies aigues communautaires de l'adulte hospitalisé avec facteur de risque , 2002 .